Muzaffar H. Qazilbash

Dec 16, 2024 | opmed.doximity.com | Muzaffar H. Qazilbash

Highlights of ASH 2024: Focus on Multiple MyelomaAccording to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple myeloma (MM) in the US, with 13,000 deaths.

Nov 14, 2023 | nature.com | Susan Bal |Luciano Costa |Muzaffar H. Qazilbash |Shaji Kumar

Dear Editor,Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by abnormal immunoglobulin light chain production, which forms insoluble fibrillary aggregates that deposit in tissues causing end-organ dysfunction. Cardiac involvement predominantly drives early mortality and influences patients’ functional status, treatment choice, and prognosis [1]. The management of AL amyloidosis focuses on clone eradication using plasma cell-directed therapies.